You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR HYDRALAZINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for hydralazine hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000499 ↗ Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) Completed National Institute on Aging (NIA) Phase 2 1980-09-01 The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints.
NCT00000499 ↗ Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1980-09-01 The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints.
NCT00000620 ↗ Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed Centers for Disease Control and Prevention Phase 3 1999-09-01 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 ↗ Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Eye Institute (NEI) Phase 3 1999-09-01 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
NCT00000620 ↗ Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 1999-09-01 The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for hydralazine hydrochloride

Condition Name

Condition Name for hydralazine hydrochloride
Intervention Trials
Hypertension 12
Heart Failure 6
Postoperative Pain 4
Hypertension in Pregnancy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for hydralazine hydrochloride
Intervention Trials
Hypertension 18
Heart Failure 11
Pre-Eclampsia 10
Hypertension, Pregnancy-Induced 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for hydralazine hydrochloride

Trials by Country

Trials by Country for hydralazine hydrochloride
Location Trials
United States 62
Mexico 6
Canada 4
Hong Kong 3
Egypt 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for hydralazine hydrochloride
Location Trials
Tennessee 7
New York 6
Ohio 5
Pennsylvania 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for hydralazine hydrochloride

Clinical Trial Phase

Clinical Trial Phase for hydralazine hydrochloride
Clinical Trial Phase Trials
Phase 4 21
Phase 3 14
Phase 2/Phase 3 1
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for hydralazine hydrochloride
Clinical Trial Phase Trials
Completed 32
Unknown status 11
Recruiting 10
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for hydralazine hydrochloride

Sponsor Name

Sponsor Name for hydralazine hydrochloride
Sponsor Trials
National Institute of Cancerología 6
Psicofarma S.A. de C.V. 5
The University of Hong Kong 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for hydralazine hydrochloride
Sponsor Trials
Other 99
NIH 9
Industry 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.